https://pharmoniq.com/news/servier-sevasemten-misses-goal-in-becker-muscular-dystrophy-study PharmoniQ en 2026-11-05T14:09:26.902Z Drug From Servier's $1.55B Deal Misses Goal in 175-Patient Study Servier, Edgewise Therapeutics, Becker muscular dystrophy, clinical trials, rare disease https://pharmoniq.com/news/ultragenyx-cuts-about-20-percent-of-staff-ends-two-rare-disease-drugs PharmoniQ en 2026-11-05T08:04:00.182Z Ultragenyx Cuts About 20% of Staff, Ends Two Rare Disease Drugs Ultragenyx, layoffs, rare disease, gene therapy, restructuring https://pharmoniq.com/news/novartis-ends-bioarctic-braintransporter-deal PharmoniQ en 2026-11-04T08:05:14.864Z Novartis Ends BioArctic Brain Delivery Deal After 14 Months Novartis, BioArctic, Partnerships, Neuroscience, Blood brain barrier https://pharmoniq.com/blog/pdufa-viii-what-fdas-next-user-fee-deal-changes PharmoniQ en 2026-11-05T10:59:42.384Z PDUFA VIII: What the FDA's Next User Fee Deal Changes PDUFA, FDA, user fees, regulatory affairs, CMC